Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.

Muge CevikLindsay C ThompsonCaryn UptonValéria Cavalcanti RollaMookho MalahlehaBlandina MmbagaNosipho NgubaneZamzurina Abu BakarMohammed RassoolEbrahim VariavaRodney DawsonSuzanne StaplesUmesh LallooCheryl LouwFrancesca ConradieMarika EristaviAnastasia SamoilovaSergey N SkornyakovNiyanda Elias NtinginyaFrederick HarakaGeorge PraygodHarriett Mayanja-KizzaJanice CaoiliVincent BalanagMargareth Pretti DalcolmoTimothy McHughRobert HuntPriya SolankiAnna BatesonAngela M CrookStella FabianeJuliano TimmEugene SunMelvin SpigelmanDerek J SloanStephen H Gillespienull null

Published in: The Lancet. Infectious diseases (2024)

TB Alliance.

Keyphrases

drug resistant
pulmonary tuberculosis
mycobacterium tuberculosis
multidrug resistant
study protocol
open label
acinetobacter baumannii
clinical trial
phase ii study
cross sectional
double blind
adverse drug
phase iii